Data from the SOFT/TEXT trials showed clinical benefit in ovarian suppression + aromatase inhibition for high risk, premenopausal women with hormone receptor positive breast cancer, making ovarian suppression a consideration that can be achieved in numerous ways. Do you titrate the dose of leuprolide, switch to goserelin, discuss oophorectomy, refer to Radiation Oncology for ovarian ablation or abandon ovarian suppression + AI altogether and go back to treating a premenopausal women with tamoxifen?